Ehsan Ansari, MD
Interventional Cardiology · Waterbury, CTNPI 1841236312
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,479 of the $6,595 with a category attached, or 67.9%. 24 manufacturers reported payments, led by Medtronic at 24.0% of the total. That places this record below the midpoint for interventional cardiology clinicians in CT, where the typical reported total is $5,446.
Across 222 payments — averaging $29.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Boston Scientific$2K
- Novartis$825
- E.r. Squibb & Sons, L.L.C.$501
- Abbott$345
- AstraZeneca$280
- plus $2K from 18 others
What the payments were for
- Travel & lodging$2,09732%
- Food & beverage$4,47968%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 9 | $1,585 |
| Boston Scientific | 41 | $1,523 |
| Novartis | 42 | $825 |
| E.r. Squibb & Sons, L.L.C. | 37 | $501 |
| Abbott | 11 | $345 |
| AstraZeneca | 16 | $280 |
| Johnson & Johnson | 18 | $279 |
| Pfizer | 12 | $216 |
| Davol Inc. | 3 | $179 |
| Edwards Lifesciences | 5 | $167 |
| Boehringer Ingelheim | 6 | $162 |
| Heartflow, Inc. | 3 | $104 |
| Cordis US CORP. | 3 | $95 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $66 |
| Alnylam Pharmaceuticals Inc. | 2 | $53 |
| Novo Nordisk | 2 | $48 |
| Abiomed | 2 | $39 |
| Amgen | 1 | $33 |
| Cardiva Medical, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Siemens Medical Solutions USA, Inc. | 1 | $18 |
| Philips North America LLC | 1 | $18 |
| Gilead | 1 | $11 |
| Altathera Pharmaceuticals LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,595 in reported general payments places this provider in the 50th percentile of 73 interventional cardiology providers in Connecticut.
See all interventional cardiology providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 769 | $878,219 |
| XareltoRivaroxaban | 376 | $451,147 |
| EntrestoSacubitril/Valsartan | 291 | $359,048 |
| Repatha SureclickEvolocumab | 175 | $207,856 |
| JardianceEmpagliflozin | 144 | $142,125 |
| BrilintaTicagrelor | 47 | $52,127 |
| MultaqDronedarone Hcl | 38 | $45,668 |
| Praluent PenAlirocumab | 56 | $44,637 |
| Repatha SyringeEvolocumab | 17 | $19,070 |
| FarxigaDapagliflozin Propanediol | 11 | $15,469 |
| Metoprolol Succinate | 1,376 | $15,177 |
| CorlanorIvabradine Hcl | 12 | $15,038 |
| Rosuvastatin Calcium | 1,073 | $14,758 |
| MounjaroTirzepatide | 15 | $13,483 |
| Ranolazine ErRanolazine | 85 | $9,375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $216 | $878,219769 claims |
| Johnson & JohnsonXarelto | $279 | $451,147376 claims |
| NovartisEntresto | $825 | $359,048291 claims |
| Boehringer IngelheimJardiance | $162 | $142,125144 claims |
| AstraZenecaBrilinta, Farxiga | $280 | $67,59558 claims |
| AmgenCorlanor | $33 | $15,03812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 73 interventional cardiology providers in Connecticut.
Other interventional cardiology in Waterbury
- Raghuraman VidhunWaterbury$12K
- Faheem Ul HaqWaterbury$7K
- Stephen WidmanWaterbury$3K
- Rebecca ScandrettWaterbury$2K
- Amit VoraNew Haven$409K
- Craig ThompsonHartford$222K
- Michael NannaNew Haven$60K
- Jawad HaiderBloomfield$44K
- Sameer NagpalNew Haven$43K
- Khagendra DahalFarmington$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.